Sacubitril/valsartan combines neprilysin inhibition with RAAS blockade. What is the net clinical effect in HFrEF?

• A. It worsens remodeling.
• B. No impact on remodeling.
• C. It improves remodeling and outcomes by neprilysin inhibition and RAAS blockade.
• D. Primarily lowers cholesterol.

Answer: (C)

The main concept is that combining neprilysin inhibition with RAAS blockade yields better remodeling and clinical outcomes in heart failure with reduced ejection fraction. Neprilysin inhibition increases levels of natriuretic peptides, bradykinin, and other peptides, promoting vasodilation, natriuresis, and anti-fibrotic effects, which help counteract harmful remodeling. Pairing this with RAAS blockade from the other component reduces angiotensin II–driven hypertension, fibrosis, and sodium retention, further limiting adverse remodeling and improving survival.

Together, these actions translate into improved cardiac structure and function and better clinical outcomes, as shown in major trials where this combination reduced cardiovascular death and HF hospitalizations compared with standard RAAS blockade alone. It also demonstrates reverse remodeling on imaging studies.

The other options don’t fit because this approach does not primarily lower cholesterol, and it does have a meaningful impact on remodeling rather than worsening it or having no effect.